Radical gastrectomy for D2 distal gastric cancer

Patient＇s information The patient is a 56-year-old man who visited our hospital for ＂repeated epigastric pain for more than two months.＂ Physical examination showed nearly pale appearance; abdomen was soft and no mass palpable; left supraclavicular lymph node （-）; and digital rectal examination （-）.

A comparative study of totally laparoscopic distal gastrectomy versus laparoscopic-assisted distal gastrectomy in gastric cancer patients: Short-term operative outcomes at a high-volume center

Objective： Laparoscopic gastrectomy has been established as a standard treatment for early gastric cancer, and its use is increasing recently. Compared with the conventional laparoscopy-assisted distal gastrectomy （LADG）, totally laparoscopic distal gastrectomy （TLDG） involves intracorporeal reconstruction, which can avoid the additional incision, resulting in pain reduction and early recovery. This study aimed to compare the short-term postoperative outcomes of TLDG vs. LADG in gastric cancer in a high-volume center.Methods： A retrospective cohort study was conducted on 1,322 patients who underwent laparoscopic distal gastrectomy from June 2012 to June 2017 at the National Cancer Center, Korea. LAD G was performed in the early period before July 2015, and TLDG was applied in the later period. Postoperative short-term outcomes were compared in terms of complication and clinical course between the two groups. Pain score was measured by rating the pain intensity from 0 to 10 points on postoperative day （POD） 1 and 3. Results： A total of 667 patients underwent LADG and 655 patients underwent TLDG. Clinieopathologic characteristics were not different in both groups. Intraoperative estimated blood loss （EBL） was significantly lower in the TLDG group （P〈0.001）. Postoperative pain scores were significantly lower in the TLDG group than in the LADG group on POD 1 （5.1±1.5 vs. 4.8±1.4, P=0.015）. First flatus passage after operation was significantly earlier in the TLDG group （3.4±0.8 d vs. 3.2±0.6 d, P〈0.001）. There were no differences in postoperative complications and hospital stay between the two groups. Conclusions： Based on the reported short-term postoperative outcomes, TLDG is safe and feasible as well as LADG. Moreover, compared with LADG, TLDG can reduce intraoperative EBL and postoperative pain and enhance the bowel motility in gastric cancer surgery.

Treatment of gastric remnant cancer post distal gastrectomy by endoscopic submucosal dissection using an insulation-tipped diathermic knife

AIM: To evaluate the effectiveness of endoscopic submucosal dissection using an insulation-tipped diathermic knife (IT-ESD) for the treatment of patients with gastric remnant cancer. METHODS: Thirty-two patients with early gastric cancer in the remnant stomach, who underwent distal gastrectomy due to gastric carcinoma, were treated with endoscopic mucosal resection (EMR) or ESD at Sumitomo Besshi Hospital and Shikoku Cancer Center in the 10-year period from January 1998 to December 2007, including 17 patients treated with IT-ESD. Retrospectively, patient backgrounds, the one-piece resection rate, complete resection (CR) rate, operation time, bleeding rate, and perforation rate were compared between patients treated with conventional EMR and those treated with IT-ESD. RESULTS: The CR rate (40% in the EMR group vs 82% in the IT-ESD group) was significantly higher in the IT-ESD group than in the EMR group; however, the operation time was significantly longer for the IT- ESD group (57.6 ± 31.9 min vs 21.1 ± 12.2 min). No significant differences were found in the rate of underlying cardiopulmonary disease (IT-ESD group, 12% vs EMR group, 13%), one-piece resection rate (100% vs 73%), bleeding rate (18% vs 6.7%), and perforation rate (0% vs 0%) between the two groups. CONCLUSION: IT-ESD appears to be an effective treatment for gastric remnant cancer post distal gastrectomy because of its high CR rate. It is useful for histological confirmation of successful treatment. Thelong-term outcome needs to be evaluated in the future.

Roux-en-Y versus BillrothⅠreconstruction after distal gastrectomy for gastric cancer:A meta-analysis

AIM:To conduct a meta-analysis to compare Rouxen-Y(R-Y) gastrojejunostomy with gastroduodenal Billroth Ⅰ(B-Ⅰ) anastomosis after distal gastrectomy(DG) for gastric cancer.METHODS:A literature search was performed to identify studies comparing R-Y with B-Ⅰ after DG for gastric cancer from January 1990 to November 2012 in Medline,Embase,Science Citation Index Expanded and the Cochrane Central Register of Controlled Trials in The Cochrane Library.Pooled odds ratios(OR) or weighted mean differences(WMD) with 95%CI were calculated using either fixed or random effects model.Operative outcomes such as operation time,intraoperative blood loss and postoperative outcomes such as anastomotic leakage and stricture,bile reflux,remnant gastritis,reflux esophagitis,dumping symptoms,delayed gastric emptying and hospital stay were the main outcomes assessed.Meta-analyses were performed using RevMan 5.0 software(Cochrane library).RESULTS:Four randomized controlled trials(RCTs) and 9 non-randomized observational clinical studies(OCS) involving 478 and 1402 patients respectively were included.Meta-analysis of RCTs revealed that R-Y reconstruction was associated with a reduced bile reflux(OR 0.04,95%CI:0.01,0.14;P < 0.00 001) and remnant gastritis(OR 0.43,95%CI:0.28,0.66;P = 0.0001),however needing a longer operation time(WMD 40.02,95%CI:13.93,66.11;P = 0.003).Metaanalysis of OCS also revealed R-Y reconstruction had a lower incidence of bile reflux(OR 0.21,95%CI:0.08,0.54;P = 0.001),remnant gastritis(OR 0.18,95%CI:0.11,0.29;P < 0.00 001) and reflux esophagitis(OR 0.48,95%CI:0.26,0.89;P = 0.02).However,this reconstruction method was found to be associated with a longer operation time(WMD 31.30,95%CI:12.99,49.60;P = 0.0008).CONCLUSION:This systematic review point towards some clinical advantages that are rendered by R-Y compared to B-Ⅰ reconstruction post DG.However there is a need for further adequately powered,welldesigned RCTs comparing the same.

Gastric cancer arising from the remnant stomach after distal gastrectomy:A review

Gastric stump carcinoma was initially reported by Balfore in 1922,and many reports of this disease have since been published. We herein review previous reports of gastric stump carcinoma with respect to epidemiology,carcinogenesis,Helicobacter pylori(H. pylori) infection,Epstein-Barr virus infection,clinicopathologic characteristics and endoscopic treatment. In particular,it is noteworthy that no prognostic differences are observed between gastric stump carcinoma and primary upper third gastric cancer. In addition,endoscopic submucosal dissection has recently been used to treat gastric stump carcinoma in the early stage. In contrast,many issues concerning gastric stump carcinoma remain to be clarified,including molecular biological characteristics and the carcinogenesis of H.pylori infection.We herein review the previous pertinent literature and summarize the characteristics of gastric stump carcinoma reported to date.

Comparison between uncut Roux-en-Y and Roux-en-Y reconstruction after distal gastrectomy for gastric cancer: A meta-analysis

AIM To compare uncut Roux-en-Y(U-RY) gastrojejunostomy with Roux-en-Y(RY) gastrojejunostomy after distal gastrectomy(DG) for gastric cancer.METHODS A literature search was conducted in Pubmed, Embase, Web of Science, Cochrane Library, Science Direct, Chinese National Knowledge Infrastructure, Wanfang, and China Science and Technology Journal Database to identify studies comparing U-RY with RY after DG for gastric cancer until the end of December 2017. Pooled odds ratio or weighted mean difference with 95% confidence interval was calculated using either fixed-or random-effects models. Perioperative outcomes such as operative time, intraoperative blood loss, and hospital stay; postoperative complications such as anastomotic bleeding, stricture and ulcer, reflux gastritis/esophagitis, delayed gastric emptying, and Roux stasis syndrome; and postoperative nutritional status(serum hemoglobin, total protein, and albumin levels) were the main outcomes assessed. Metaanalyses were performed using RevM an 5.3 software.RESULTS Two randomized controlled trials and four nonrandomized observational clinical studies involving 403 and 488 patients, respectively, were included. The results of the meta-analysis showed that operative time [weighted mean difference(WMD):-12.95; 95%CI:-22.29 to-3.61; P = 0.007] and incidence of reflux gastritis/esophagitis(OR: 0.40; 95%CI: 0.20-0.80; P = 0.009), delayed gastric emptying(OR: 0.29; 95%CI: 0.14-0.61; P = 0.001), and Roux stasis syndrome(OR: 0.14; 95%CI: 0.04-0.50; P = 0.002) were reduced; and the level of serum albumin(WMD: 0.71; 95%CI: 0.24-1.19; P = 0.003) was increased in patients undergoing U-RY reconstruction compared with those undergoing RY reconstruction. No differences were found with respect to intraoperative blood loss, hospital stay, anastomotic bleeding, anastomotic stricture, anastomotic ulcer, the levels of serum hemoglobin, and serum total protein. CONCLUSION U-RY reconstruction has some clinical advantages over RY reconstruction after DG.

Progression of remnant gastric cancer is associated with duration of follow-up following distal gastrectomy

AIM: To re-evaluate the recent clinicopathological features of remnant gastric cancer (RGC) and to develop desirable surveillance programs. METHODS: Between 1997 and 2008, 1149 patients underwent gastrectomy for gastric cancer at the Department of Digestive Surgery, Kyoto Prefectural University of Medicine, Japan. Of these, 33 patients underwent gastrectomy with lymphadenectomy for RGC. Regarding the initial gastric disease, there were 19 patients with benign disease and 14 patients with gastric cancer. The hospital records of these patients were reviewed retrospectively. RESULTS: Concerning the initial gastric disease, the RGC group following gastric cancer had a shorter interval [P < 0.05; gastric cancer vs benign disease: 12 (2-22) vs 30 (4-51) years] and were more frequently reconstructed by Billroth-Ⅰ procedure than those following benign lesions (P < 0.001). Regarding reconstruction, RGC following Billroth-Ⅱ reconstruction showed a longer interval between surgical procedures [P < 0.001; Billroth-Ⅱ vs Billroth-Ⅰ: 32 (5-51) vs 12 (2-36) years] and tumors were more frequently associated with benign disease (P < 0.001) than those following Billroth-Ⅰ reconstruction. In tumor location of RGC, after Billroth-Ⅰ reconstruction, RGC occurred more frequently near the suture line and remnant gastric wall. After Billroth-Ⅱ reconstruction, RGC occurred more frequently at the anastomotic site. The duration of follow-up was significantly associated with the stage of RGC (P < 0.05). Patients diagnosed with early stage RGC such as stage Ⅰ-Ⅱ tended to have been followed up almost every second year. CONCLUSION: Meticulous follow-up examination and early detection of RGC might lead to a better prognosis. Based on the initial gastric disease and the procedure of reconstruction, an appropriate follow-up interval and programs might enable early detection of RGC.

The F5 gene predicts poor prognosis of patients with gastric cancer by promoting cell migration identified using a weighted gene co-expression network analysis

Distal gastric cancer(DGC)is a subgroup of gastric cancer(GC),which has different molecular characteristics from proximal gastric cancer(PGC).These differences result in different overall survival(OS)rates;however,data pertaining to the survival rate in PGC or DGC are contradictory.This suggests that the location of GC is not the unique cause of the different survival rates,while the molecular characteristics might be more important factors determining the prognosis of DGC.Therefore,the aim of this study was to discover key prognostic factors in DGC using bioinformatic methods and to explore the potential molecular mechanism.The Cancer Genome Atlas(TCGA)public database was employed to screen data relating to DGC,and we conducted a weighted gene co-expression network analysis(WGCNA)on DGC patient samples to establish co-expression modules.High-weight genes(hub genes)in a dominant color module were identified.In vitro experiments and gene set enrichment analyses(GSEA)were carried out to elucidate the potential molecular mechanism.In this study,139 DGC samples were enrolled to perform a co-expression analysis.According to the correlation between gene modules and clinical characteristics,the royal blue module related to stage M of DGC was screened,and a survival analysis was conducted to show that highcoagulation-factor V(F5)expression was related to the short OS of patients with GC.In vitro experiments confirmed that F5 could promote the migration of GC cells.GSEA suggested that F5 might have affected the prognosis of GC by modulating the activities of the Wnt and/or the TGF-βsignaling pathways.Our results indicated that high F5 expression predicts poor prognosis of patients with DGC,and it functions probably by promoting cell migration through the Wnt and/or the TGF-βsignaling pathways.

Roux-en-Y reconstruction does not require gastric decompression after radical distal gastrectomy

AIM: To determine whether routine nasogastric (NG) decompression benefitted patients undergoing radical gastric surgery. METHODS: Between January 1998 and December 2008, 519 patients who underwent distal gastrectomy for gastric cancer were retrospectively divided into 2 time-period cohorts; those treated with Billroth Ⅱ (BⅡ) reconstruction in the first 6 years and those with Roux-en-Y (RY) reconstruction in the last 5 years. In the latter group, the patients were further divided into 2 subgroups; with and without nasogastric decompression.RESULTS: Postoperatively, there were no significant differences in the number of anastomotic leaks between the 3 groups. In the tubeless RY group, time to semiliquid diet was significantly shorter than in the other 2 groups (4.4 d ± 1.4 d vs 7.2 d ± 1.3 d and 5.9 d ± 1.2 d, P = 0.005). The length of postoperative stay was significantly increased in patients with BⅡ reconstruction compared with patients with RY reconstruction with/without NG decompression (15.4 d ± 4.3 d in BⅡ group vs 12.6 d ± 3.1 d in decompressed RY and 11.4 d ± 3.4 d in the tubeless RY group, P = 0.035). The postoperative pneumonia rate was lowest in the tubeless group and highest in the BⅡ group (1.4% vs 4.6%, P = 0.01). Severe sore throat was noted in 59 (20.7%) members of the BⅡ group, 18 (17.4%) members of the decompressed RY group and 6 (4.2%) members of the tubeless RY group. Fewer patients in the tubeless group complained of severe sore throat (P = 0.001). CONCLUSION: This study provides support for abandoning routine NG decompression in patients undergoing subtotal gastrectomy with Roux-en-Y gastrojejunostomy.

Strategies for gastric cancer in the modern era

Gastric cancer is one of the most common neoplasms in Japan, and it is also the second leading cause of cancer-related deaths worldwide. Nowadays, infection with Helicobacter pylori (H. pylori) is a known risk factor for the development of gastric cancer. Therefore, gastric cancer should be considered as an infectious disease, and in fact, prophylactic eradication of H. pylori may prevent the development of metachronous gastric carcinoma. Before the role of H. pylori was understood, a different approach was used. Recently even after the cancer has developed, some newer therapeutic approaches have been pursued. These newer treatments have been summarized as "minimally invasive therapies" and use endoscopic or laparoscopic techniques. In addition, robotic approaches are being developed that seem to hold a great potential to change the surgical approach. Since basic understanding and treatment of the disease have both changed signif icantly over the last decade, we present a review of current advances in gastric cancer research and therapy.

Surgical resection of gastric stump cancer following proximal gastrectomy for adenocarcinoma of the esophagogastric junction

BACKGROUND Proximal gastrectomy(PG) is performed widely as a function-preserving operation for early gastric cancer located in the upper third of the stomach and is an important function-preserving approach for esophagogastric junction(EGJ)adenocarcinoma. The incidence of gastric stump cancer(GSC) after PG is increasing. However, little is known about the GSC following PG because very few studies have been conducted on the disease.AIM To clarify clinicopathologic features, perioperative complications, and long-term survival rates after the resection of GSC following PG.METHODS Data for patients with GSC following PG for adenocarcinoma of the EGJ diagnosed between January 1998 and December 2016 were retrospectively reviewed. Multivariate analysis was performed to identify factors associated with overall survival(OS). GSC was defined in accordance with the Japanese Gastric Cancer Association.RESULTS A total of 35 patients were identified. The median interval between the initial PGand resection of GSC was 4.9(range 0.7-12) years. In 21 of the 35 patients, the tumor was located in a nonanastomotic site of the gastric stump. Total gastrectomy was performed in 27 patients; the other 8 underwent partial gastrectomy. Postoperative complications occurred in 6 patients(17.1%). The tumor stage according to the depth of tumor invasion was T1 in 6 patients, T2 in3 patients, T3 in 9 patients, and T4 in 17 patients. Lymph node metastasis was observed in 18 patients. Calculated 1-, 3-, and 5-year OS rates were 86.5%, 62.3%,and 54.2%, respectively. Multivariate analysis showed advanced T stage to be associated with OS.CONCLUSION This study reveals the characteristics of GSC following PG for adenocarcinoma of the EGJ and suggests that a surgical approach can lead to a satisfactory outcome.

Laparoscopic gastric surgery for cancer: Where do we stand?

Gastric cancer poses a significant public health problem, especially in the Far East, due to its high incidence in these areas. Surgical treatment and guidelines have been markedly different in the West, but nowadays this debate is apparently coming to an end. Laparoscopic surgery has been employed in the surgical treatment of gastric cancer for two decades now, but with controversies about the extent of resection and lymphadenectomy. Despite these difficulties, the apparent advantages of the laparoscopic approach helped its implementation in early stage and distal gastric cancer, with an increase on the uptake for distal gastrectomy for more advanced disease and total gastrectomy. Nevertheless, there is no conclusive evidence about the laparoscopic approach yet. In this review article we present and analyse the current status of laparoscopic surgery in the treatment of gastric cancer.

GATA结合蛋白3和粘蛋白1在近端和远端胃癌组织中的表达及临床意义

目的探究GATA结合蛋白3(GATA3)和粘蛋白1(MUC1)在近端胃癌(PGC)和远端胃癌(DGC)组织中的表达及临床意义。方法收集孝感市中心医院2014年2月至2016年3月收治的121例胃癌患者经手术切除的胃癌组织及癌旁组织标本,根据肿瘤发生位置将患者分为PGC组(n=62)和DGC组(n=59),采用实时荧光定量PCR检测两组胃癌组织及癌旁组织中GATA3和MUC1的表达水平;免疫组织化学法检测GATA3和MUC1在各样本中的阳性表达情况,分析GATA3、MUCI与PGC和DGC临床病理特征的关系;Pearson法分析PGC和DGC胃癌组织中GATA3和MUC1表达相关性;Kaplan-Meier曲线分析GATA3和MUC1表达与两组患者5年生存率的关系。结果两组胃癌组织中GATA3和MUC1的表达水平及阳性表达率均高于两组癌旁组织(P<0.05),且PGC组胃癌组织中GATA3、MUCI的表达水平及阳性表达率均明显高于DGC组胃癌组织(P<0.05);两组胃癌组织中GATA3和MUC1的表达呈显著正相关(P<0.05);两组胃癌组织中GATA3和MUC1阳性表达水平与肿瘤TNM分期、淋巴结转移、分化程度以及浸润程度有关(P<0.05);而与患者年龄、性别及肿瘤大小无关(P>0.05),两组GATA3和MUC1阳性表达者的5年生存率低于阴性表达者(P<0.05)。结论GATA3和MUC1在PGC和DGC患者胃癌组织中的表达水平显著增加,且二者的表达与患者临床病理特征及预后有关。

腹腔镜下远端胃癌切除后消化道不同重建方式对患者预后影响分析

目的:探究腹腔镜下远端胃癌切除后消化道不同重建方式对患者预后的影响。方法:回顾性分析107例腹腔镜下远端胃癌切除后消化道重建患者的临床资料,术后均随访1年。根据患者消化道重建方式不同分为Ⅰ组(n=30)、II组(n=28)和R组(n=49),Ⅰ组采取Billroth-Ⅰ式吻合;Ⅱ组患者采取Billroth-Ⅱ式联合布朗吻合;R组患者采取Roux-en-Y吻合。探究各组围术期情况,比较各组术后3周内及术后1年时并发症发生情况。结果:Ⅰ组患者手术时间低于Ⅱ组及R组(P<0.05);各组患者术后3周内并发症发生率比较,差异均无统计学意义(P>0.05);术后1年,R组患者胆汁反流、反流性胃炎发生率低于Ⅰ组及Ⅱ组(P<0.05)。结论:Billroth-Ⅰ式吻合有助于缩短手术时间,但Roux-en-Y吻合在术后远期效果更具优势。

胃良性疾病患者行远端胃切除术后发生残胃癌和食管癌的危险因素分析

目的:探讨胃良性疾病患者行远端胃切除术后残胃癌和食管癌发生的相关危险因素。方法:回顾性分析2010年01月01日至2018年01月01日因胃良性疾病在我院行远端胃切除术的患者的病历资料,采用单因素分析和多因素logistic回归模型确定术后残胃癌和食管癌发生的独立危险因素,并建立远端胃切除术后食管癌、残胃癌发生风险的预测模型。结果:共纳入301例患者,残胃癌患者占11.96%,平均年龄(67.83±9.14)岁,其中进展期患者占83.33%,且只有55.56%的患者有手术机会,残胃癌多见于残胃体及吻合口。5.00%的患者发生了食管癌,平均年龄(68.00±8.73)岁,多见于食管下1/3段,均为进展期,且80.00%失去了手术机会。单因素和二元logistic回归分析显示,年龄≥65岁、手术间隔≥10年和胆汁反流是残胃癌的独立危险因素,年龄≥65岁和胆汁反流是食管癌的独立危险因素。将残胃癌和食管癌发生风险分为低危、中危、高危组,残胃癌在各组发生率分别为1.72%、8.62%、28.99%(P<0.001),食管癌分别为0.70%、4.88%、13.16%(P<0.001)。结论:年龄≥65岁、手术间隔≥10年的因胃良性疾病行远端胃切除术后的患者,建议密切进行胃镜随访。如发现胆汁反流,应仔细检查食管下1/3段、残胃体及吻合口。

单孔+1孔对比传统多孔3D腹腔镜手术治疗进展期远端胃癌的近期疗效回顾性研究

目的对比单孔+1孔3D腹腔镜手术(SILS+1)与传统多孔3D腹腔镜手术(CLS)对进展期远端胃癌患者的近期疗效差异。方法回顾性分析2021年3月至2022年11月我院胃肠外科收治的245例进展期远端胃癌患者资料,按照手术方式的不同分为CLS组(n=125)和SILS+1组(n=120例),对比分析临床资料及指标包括:基线资料、手术时间、术中失血量及输血量、皮下气肿发生率、中转开腹情况、切除淋巴结总数、切缘阴性率、术后疼痛评分(VAS)、切口美容评分、术后肠内外营养时间、术后住院时间、围术期并发症发生率、总费用等。结果两组患者术前的年龄、性别、体质指数(BMI)、肿瘤术前分期、既往基础病史(高血压、糖尿病、COPD、冠心病、腹部手术史)、肿瘤位置及是否合并幽门梗阻方面等基线指标相比较,差异均无统计学意义(P>0.05)。SILS+1组切口美容评分SCAR更高[(2.10±0.40)分vs.(3.29±0.51)分,P<0.05],术中失血量更少[(94.29±107.65)ml vs.(126.64±104.58)ml,P<0.05],术后胃肠道功能恢复更快[(2.59±0.56)d vs.(2.90±0.50)d,P<0.05]。SILS+1组手术耗时更长[(231.21±40.58)min vs.(203.66±54.78)min],气管插管时间也更长[(273.00±48.16)min vs.(249.22±62.72)min],但是其术中切除淋巴结总数更为彻底,切除数量更多[(28.14±12.02)vs.(24.14±11.53)],差异均有统计学意义(P<0.05)。SILS+1组患者术后第1天、术后第2天、术后第4天VAS评分较CLS组更低,差异有统计学意义(P<0.05)。两组患者肿瘤切缘均为阴性,在术中输血、中转开腹情况、皮下气肿发生率方面差异无统计学意义(P>0.05)。两组患者在术后3天的腹腔引流量、肠内外营养时间、住院时长和住院费用上并无差异(P>0.05)。在术后并发症方面,SILS+1组出现4例深静脉血栓事件、CLS组出现5例,两组中均出现1例全身炎症反应综合征,差异无统计学意义(P>0.05),而SILS+1组肺部感染、腹腔感染、切口感染、吻合口瘘、术后出血、肠梗阻等不良事件的发生率要低于CLS组,差异有统计学意义(P<0.05)。结论就围手术期并发症及术后早期恢复指标而言,SILS+1治疗进展期远端胃癌的近期疗效优于CLS,但SILS+1手术时间略长于CLS,SILS+1治疗进展期远端胃癌的价值亟待高质量的多中心随机对照试验进一步研究。

毕Ⅱ式联合Braun与单纯毕Ⅱ式吻合在腹腔镜远端胃癌根治术中疗效比较的Meta分析

目的系统评价BillrothⅡ式与BillrothⅡ式联合Braun吻合重建术在腹腔镜远端胃癌根治术中的临床疗效差异。方法计算机检索CNKI、VIP、万方数据库、PubMed、Embase、Web of Science等,收集国内外公开发表关于两种消化道重建方式在腹腔镜远端胃癌根治术中比较的临床应用研究。检索时限为2000年1月至2022年10月。对纳入的临床研究进行质量评价及数量提取,并采用Cochrane协作网提供的RevMan5.3统计软件进行Meta分析。结果共纳入9项符合标准的研究,共1483例患者。Meta分析结果显示:在腹腔镜远端胃癌根治术中使用单纯BillrothⅡ式吻合手术时间及消化道重建时间短、术中出血量少,但使用BillrothⅡ联合Braun吻合住院时间短、近期总并发症少、远期反流性疾病少、远期营养状况好,差异均有统计学意义(P<0.05)。而淋巴结清扫数量、首次排气排便时间及部分短期并发症,差异无统计学意义(P>0.05)。结论腹腔镜远端胃癌根治术中,与单纯BillrothⅡ吻合相比,应用BillrothⅡ式联合Braun重建消化道,虽延长手术时间并增加术中出血量,但能减少患者术后近、远期并发症,减少术后住院时间,改善患者远期营养状况,临床应用具有一定优势。

比较完全腹腔镜与腹腔镜辅助远端胃癌根治术治疗局部AGC患者的疗临床疗效

目的:比较完全腹腔镜远端胃癌根治术(Totally laparoscopic distal gastrectomy,TLDG)、腹腔镜辅助远端胃癌根治术(Laparoscopy-assisted distal gastrectomy,LADG)治疗局部进展期胃癌(Advanced gastric carcinoma,AGC)患者的临床疗效。方法:选取周口东新医院2021年6月至2023年6月收治的90例局部AGC患者,根据手术方法不同,分为腹腔镜辅助组和完全腹腔镜组,各45例。完全腹腔镜组采用TLDG术,腹腔镜辅助组行LADG术。手术过程中,记录并比较两组术中出血量、手术切口长度、手术时间、淋巴结清扫数量;术后,记录并比较两组首次自主下床活动时间、术后首次排气时间、首次流食进食时间、住院天数;术前、术后3d和术后7d,采用酶联免疫吸附法检测血清肿瘤坏死因子-α(Tumor necrosis factor,TNF-α)、C反应蛋白(C-reactive protein,CRP)、白细胞介素-6(Interleukin-6,IL-6);术后,记录并比较两组并发症发生情况。结果:完全腹腔镜组手术时间、手术切口长度短于腹腔镜辅助组,术中出血量少于腹腔镜辅助组(P<0.05);完全腹腔镜组术后首次排气时间、首次自主下床活动时间、首次流食进食时间、住院天数均短于腹腔镜辅助组(P<0.05);与术前比较,两组术后3d和术后7 d血清TNF-α、CRP、IL-6水平均呈先升高后降低趋势,其中完全腹腔镜组更低(P<0.05);完全腹腔镜组并发症总发生率明显低于腹腔镜辅助组(P<0.05)。结论:与LADG术相比,TLDG术术中出出血量更少、切口更小,创伤炎性反应更轻,并发症的发生率更低,可加快术后康复进程,促进患者早日康复。

腹腔镜辅助远端胃癌根治术不同Uncut Roux-en-y吻合方式对病人的疗效及对肿瘤标志物和预后的影响

目的探讨不同Uncut Roux-en-y吻合方式对胃癌病人的疗效及对其检验指标和预后的影响。方法我院2018年3月~2021年2月收治的远端胃癌病人96例,均行腹腔镜辅助远端胃癌根治术,根据吻合方式分为两组,其中研究组46例,采用改良U-RY吻合术治疗,对照组病人50例,采用U-RY吻合术治疗,比较两组病人的围术期指标(手术时间、术中出血量、首次通气时间、住院时间及术后第1天引流量)、手术前后肿瘤相关指标(CEA、CA19-9)、术后并发症及术后1年的预后情况。结果除术后第1天引流量外,研究组的其余指标(手术时间、术中出血量、首次通气时间和住院时间)优于对照组(P<0.05);术前两组的肿瘤相关指标(CA19-9、CEA)比较无明显差异(P>0.05),术后两组病人的肿瘤相关指标(CA19-9、CEA)均较术前降低,差异有统计学意义(P<0.05);研究组总并发症发生率比对照组低(8.7%vs 30.0%,P<0.05);术后1年,两组病人的生存率和复发率比较无明显差异(97.8%vs 96.0%,4.3%vs 6.0%,P>0.05)。结论腹腔镜辅助远端胃癌根治术中应用改良U-RY吻合术可显著缩短病人的手术时间,加快病人的康复速度,且可降低其术后并发症发生率,最终不影响病人的预后。

系统免疫炎症指数与营养控制状态评分对老年早期远端胃癌全腔镜手术病人预后的评估价值

目的 探究系统免疫炎症指数(SⅡ)与营养控制状态(CONUT)评分对老年早期远端胃癌全腔镜手术病人预后的预测效能。方法 选择2019年1月至2022年1月我院收治的行全腔镜胃癌切除术的老年早期远端胃癌病人126例,术前3 d检测外周血血小板、淋巴细胞计数、中性粒细胞、血清白蛋白及总胆固醇水平,计算SⅡ及CONUT评分。根据术后6个月随访结果将病人分为预后良好组和预后不佳组,采用多因素Logistic回归分析影响老年早期远端胃癌病人预后的相关因素。以ROC曲线下面积(AUC)评估SⅡ及CONUT评分对老年早期远端胃癌病人预后的预测价值。结果 126例老年早期远端胃癌病人中预后不佳24例。单因素及多因素Logistic回归分析结果均显示,年龄大、SⅡ升高、CONUT评分较高及浸润黏膜肌层M3为老年早期远端胃癌病人不良预后的危险因素(P<0.05)。ROC曲线分析结果显示,SⅡ及CONUT评分单一及联合预测老年早期远端胃癌病人不良预后的AUC分别为0.706(95%CI:0.610~0.852)、0.701(95%CI:0.594~0.826)、0.809(95%CI:0.759~0.941),两者单一预测效能低于联合预测(P<0.05)。结论 SII及CONUT评分可用于辅助评估老年早期远端胃癌病人的预后,且预测效能良好。